Home Blog Page 886

GSCF Launches C4: Connected Capital Control Center

By
Advertorial Desk
-

Delivering Visibility and Control to Corporates, Banks & Asset Managers

NEW YORK, March 26, 2026 /PRNewswire/ — GSCF, a leading global provider of working capital solutions, today announced the launch of Connected Capital Control Center (C4) – a servicing platform designed to help banks, asset managers and enterprise corporates originate, manage and analyze working capital with greater visibility, control and confidence across multiple programs.

Built to support GSCF’s Connected Capital ecosystem and the broader market landscape, C4 addresses a growing market need: organizations are deploying multiple working capital programs across regions, funders, insurers and service providers, yet lack a single source of truth to track exposure, liquidity, cost and risk across their entire portfolio of programs.

C4 consolidates program data and workflows into one unified control layer for programs serviced by GSCF or external providers, enabling financial institutions and enterprises to scale working capital more efficiently while reducing operational friction and risk.

“As working capital portfolios grow more complex, fragmented views and manual oversight aren’t sustainable,” said Doug Morgan, Chief Executive Officer of GSCF. “C4 brings portfolio-level clarity to enterprises and their funding partners – so decisions can be made with confidence, limits can be enforced proactively, and working capital can be deployed more strategically across the global ecosystem.”

C4 for Enterprise Corporates: Advanced Intelligence for the Office of the CFO

For global enterprises relying on multiple working capital programs across regions, funders and administrators to drive liquidity and fuel growth, C4 provides a single, aggregated view of all working capital activity to eliminate data silos and enable centralized oversight.

Key capabilities for corporates include:

  • Aggregated Data Views: A single source of truth consolidating all working capital programs, regardless of funder or platform
  • Portfolio-Level Intelligence: Holistic visibility across regions, buyers, suppliers and counterparties to support CFO- and Treasurer-level decisioning
  • Cross-Funder Transparency: Clear insight into funding flows, utilization and pricing across multiple banks and capital partners
  • Global Operational Workflows: Standardized and automated processes designed for multi-region, multi-funder environments
  • Exposure and Concentration Management: Program- and portfolio-level analytics to identify risk, adjust limits and optimize capital allocation

By unifying data and decisioning at the portfolio level, C4 allows enterprises to move beyond reactive reporting and manage working capital as a strategic asset.

C4 for Banks: Scaling Working Capital with Confidence and Control

For trade finance and structured working capital teams, C4 delivers real-time visibility and embedded controls across multi-program and multi-funder portfolios to enable faster origination, stronger governance and scalable growth.

Key capabilities for banks include:

  • Portfolio-Level Visibility: A consolidated, real-time view of exposure across obligors, regions, insurers and structures
  • Built-In Limit Management: Embedded credit limits, concentration thresholds, alerts and automated “pause” mechanisms
  • Streamlined Accounts Receivable: Standardized AR processes that scale from simple programs to complex, insured structures
  • Co-Origination and Extended Capacity: A unique combination of servicing expertise and funding capabilities that expands balance-sheet flexibility

C4 empowers banks to shift from a model of program-by-program oversight to true portfolio management, reducing blind spots while increasing confidence in the ability to grow with efficiency and discipline.

A Control Center Built for Scale, Not Silos

Unlike today’s working capital landscape that can be fragmented across operations, technology and data, C4 is designed as a portfolio-level control layer that integrates technology with GSCF’s world-class managed services. Backed by more than 30 years of experience operating complex working capital programs globally, GSCF embeds operational precision directly into the platform – allowing clients to offload complexity while fully retaining control.

“C4 addresses the needs of banks and enterprises today while supporting their growth across multiple programs, partners and jurisdictions,” said Shannon Dolan, Chief Product Officer of GSCF. “By consolidating data, limits, workflows and decisioning into one control center, C4 will help teams act faster, reduce risk and continuously optimize working capital performance at scale.”

“The evolution of working capital management is moving beyond process efficiency toward liquidity orchestration. As enterprises and their financial partners deploy programs across an increasingly complex ecosystem of funders, regions and structures, the demand for portfolio-level visibility and control is intensifying. C4 reflects where the market is heading – a unified control layer that enables CFOs and Treasurers to manage liquidity not just as an operational necessity, but as a driver of business performance and resilience,” said Senior Research Director, IDC Enterprise Applications, Kevin Permenter.

About GSCF

GSCF is the leading global provider of working capital solutions. The Company enables corporates and financial partners to accelerate growth, unlock liquidity and manage the risk and complexity of the end-to-end working capital cycle. We originate, manage and analyze working capital programs through our innovative Working Capital as a Service offering, combining the power of a configurable and comprehensive technology platform, expert services and a Connected Capital ecosystem of alternative capital solutions and bank capital. GSCF’s team of working capital experts operates in over 75 countries to solve global working capital efficiency challenges. Visit www.gscf.com to learn more.

Media Contact:
Natalie Silverman
Chief Marketing Officer at GSCF
natalie.silverman@gscf.com 

Neurophet Signs MOU with ALZ-NET to Facilitate Imaging Monitoring Infrastructure for Alzheimer’s Disease Therapies

By
Advertorial Desk
-
  • Aims to improve quality of care for patients with Alzheimer’s disease… Exploring adoption of Neurophet’s key solutions
  • Collaboration expected to leverage Neurophet AQUA, Neurophet SCALE PET and Neurophet AQUA AD Plus

SEOUL, South Korea, March 26, 2026 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a memorandum of understanding (MOU) with the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET).

Neurophet Signs MOU with ALZ-NET
Neurophet Signs MOU with ALZ-NET

The agreement aims to support healthcare professionals participating in ALZ-NET and enhance the quality of care for patients with Alzheimer’s disease. Under the partnership, the two parties will work to raise awareness of the importance of monitoring Amyloid-Related Imaging Abnormalities (ARIA), while also providing discounted access to Neurophet’s key solutions across medical institutions participating in ALZ-NET and expanding their clinical utilization.

The collaboration will involve Neurophet’s flagship solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software; Neurophet SCALE PET, a quantitative Positron Emission Tomography (PET) imaging analysis software; Neurophet AQUA AD Plus, an integrated brain imaging analysis solution designed to support treatment decision-making for Alzheimer’s disease therapies.

Neurophet AQUA, Neurophet SCALE PET, and Neurophet AQUA AD Plus have each received 510(k) clearance from the U.S. Food and Drug Administration (FDA). A number of Alzheimer’s disease treatment medical centers and neuroimaging facilities participating in ALZ-NET are expected to leverage Neurophet’s key solutions going forward.

Sponsored by the Alzheimer’s Association and managed and operated by the American College of Radiology (ACR), ALZ-NET is an Alzheimer’s treatment and diagnostics network that collects and analyzes clinical and imaging data from patients receiving novel FDA-approved Alzheimer’s therapies through voluntarily participating medical institutions. Through these efforts, ALZ-NET supports the advancement of clinical evidence and the standardization of care in the field of Alzheimer’s treatment and diagnostics.

Ana Franceschi, MD, PhD, Chair of the ACR Neuroradiology Research Committee and member of the ALZ-NET Imaging Workgroup, stated, “We are pleased to collaborate with Neurophet to bring their innovative imaging solution to ALZ-NET sites. Strengthening imaging infrastructure across the network is essential to providing high-quality care as Alzheimer’s treatment continues to advance.”

Jake Junkil Been, Co-CEO of Neurophet, said, “With ALZ-NET, Neurophet aims to contribute the establishment of an imaging-based monitoring infrastructure that is essential in the era of Alzheimer’s therapies. We will contribute to enhance the overall quality of the Alzheimer’s treatment ecosystem in the United States.”

About Neurophet

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software “Neurophet AQUA”, PET Image Quantitative Analysis Software “Neurophet SCALE PET”, Brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”, Alzheimer’s Disease treatment prescription and monitoring software “Neurophet AQUA AD” for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software “Neurophet AQUA MS”.

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.

The Pinkfong Company Introduces AI Voice-Powered Fan Creation for New IP “REDREX”

By
Advertorial Desk
-
  • Partners with HYBE’s Supertone to enable fan-created content using REDREX AI voices
  • Surpassed 500K followers and 21M TikTok views since its October 2025 debut

SEOUL, South Korea, March 26, 2026 /PRNewswire/ — The Pinkfong Company, the global entertainment company behind Baby Shark, today announced a collaboration with HYBE’s AI voice technology company Supertone to expand fan-driven content creation for its new IP, REDREX.

The Pinkfong Company Introduces AI Voice-Powered Fan Creation for New IP “REDREX”
The Pinkfong Company Introduces AI Voice-Powered Fan Creation for New IP “REDREX”

Through the partnership, official character voices from REDREX will be available on Supertone Play, Supertone’s AI voice creation platform. By making character-based text-to-speech (TTS) voices, the companies aim to enable fans to create memes, dubbed videos, and other short-form content using REDREX character voices.

REDREX is a short-form animated office comedy designed for social platforms. The series centers on Rex, a “workaphobic” dinosaur who seems to be allergic to work — especially Mondays. Each episode runs approximately one to three minutes and humorously captures the ups and downs of office life. The series resonates with Gen Z and millennials navigating the humor and challenges of modern workplace culture.

As part of the collaboration, Supertone Play will leverage its advanced voice models, including Sona Speech 1 and Sona Speech 2, which support 23 languages and deliver highly expressive, natural-sounding performances. Supertone is an AI audio technology company whose technology has been used in productions on major streaming platforms. The company develops hyper-realistic voices capable of both acting and singing, empowering creators to craft more immersive and engaging content.

Since its initial release on social media in October 2025, REDREX has quickly gained traction online. The brand’s social channels have surpassed 500,000 followers, while TikTok videos have generated more than 21 million views, with particularly strong engagement from audiences in North America. New episodes are released every Sunday on the official REDREX YouTube channel.

“REDREX has gained strong traction in North America since its debut on social media,” said Bitna Kwon, Chief Strategy Officer at The Pinkfong Company. “Through our partnership with Supertone, we hope to introduce REDREX to even more fans and unlock new forms of fan-created content powered by AI voice technology.”

Download images here

About The Pinkfong Company
The Pinkfong Company is a global entertainment company that delivers content and entertaining experiences around the world. Driven by award-winning brands and IPs, the company has created and distributed a range of content across genres and formats including original animated series, world live tours, interactive games, and more. Believing in the power of entertaining and engaging content, The Pinkfong Company is committed to connecting people around the world and bringing joy and inspiration to worldwide audiences of all ages. For more information, please visit the website or follow the company on LinkedIn.

Media Contact
Hailey Kim
Communications Manager
The Pinkfong Company
hailey@pinkfong.com

Addentax Group Corp. Announces Reverse Stock Split

By
Advertorial Desk
-

SHENZHEN, China, March 26, 2026 /PRNewswire/ — Addentax Group Corp. (Nasdaq: ATXG) (the “Company”) announced today that following the stockholder approval of the reverse stock split proposal at the Company’s 2025 Annual Meeting of Stockholders held on January 30, 2026, the Board of Directors of the Company, on March 19, 2026, approved a reverse stock split of the Company’s common stock at a ratio of 1-for-15 (the “Reverse Stock Split”) and authorized the filing of a Certificate of Amendment to the Company’s Articles of Incorporation (the “Amendment”) to effect the Reverse Stock Split.

On March 24, 2026, the Company filed the Amendment with the Secretary of State of the State of Nevada to effect the Reverse Stock Split. The Amendment will become effective at 12:01 a.m. (Eastern Time) on March 30, 2026 (the “Effective Time”).

As a result of the Reverse Stock Split, every fifteen (15) shares of common stock outstanding immediately prior to the Effective Time will be reclassified and combined into one share of common stock, without any change in the par value of $0.001 per share or the total number of authorized shares. Beginning with the opening of trading on March 30, 2026, the Company’s common stock will be available for trading on the Nasdaq Capital Market under the symbol “ATXG” on a Reverse Stock Split adjusted basis with a new CUSIP number (00653L400).

No fractional share will be issued in connection with the foregoing combination of the shares pursuant to the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split will receive one whole share of common stock in lieu of such fractional share.

The Company’s transfer agent, Transfer Online, Inc., is acting as the exchange agent for the Reverse Stock Split. Stockholders who hold their shares in book-entry form or in “street name” (i.e., through a broker, bank or other holder of record) are not required to take any action. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except for minor changes resulting from the treatment of fractional shares.

About Addentax Group Corp.

Addentax Group Corp. is an integrated service provider specializing in garment manufacturing and logistics services. For more information about the Company, please visit the website: https://www.addentax.com/.

Caution Concerning Forward Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the SEC, that may affect the Company’s future results. All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended March 31, 2025. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Company Contact:

Public Relations Contact:
Addentax Group Corp.
Phone: + (86) 755 86961 405
yoongxin.chan@zgyingxi.com

Investor Relations Contact:

Sherry Zheng
WAVECREST GROUP INC.
1-718-213-7386
sherry@wavecrestipo.com

Bybit Launches AED Fiat Referral Boost Campaign with 7,500 USDT Prize Pool

By
Advertorial Desk
-

DUBAI, UAE, March 26, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is excited to launch  AED Fiat Referral Boost, an exclusive rewards initiative exclusive for AED fiat deposits on Bybit. From now until April 26, 2026, participants stand to win a share of a 7,500 USDT prize pool through eligible deposits or successful referrals.

The AED Fiat Referral Boost incentivizes both new and existing users to deposit AED through Bybit’s robust local fiat deposit rails while inviting friends to share in the experience. Participants can earn USDT airdrops through first-deposit bonuses, tiered deposit milestones, and a competitive leaderboard for top referrers.

Highlights

  • First Deposit Double Reward: Referrers earn 5 USDT for each qualified new user (up to 10 referees); new depositors receive 10 USDT upon completing their initial AED 500+ deposit.
  • High-Intent Deposit Booster: New users can earn up to 30 USDT by depositing AED 10,000 or more, with rewards tiered at AED 2,000, 4,000, 8,000, and 10,000 thresholds.
  • Power Referrer Leaderboard: The top three referrers with the most qualified AED depositors compete for 300 USDT, 200 USDT, and 100 USDT respectively.

Headquartered in the UAE since 2022, Bybit was proud to have received the UAE’s first Virtual Asset Platform Operator License from the Capital Market Authority (former SCA) in 2025.

With its growing suite of regulated solutions and offerings in the local market, Bybit remains steadfast in its commitment to supporting the UAE community during the current challenging times. The launch of the AED Fiat Referral Boost reflects Bybit’s confidence in the region’s economic strength and dedication to fostering financial accessibility and resilience. 

Bybit Launches AED Fiat Referral Boost Campaign with 7,500 USDT Prize Pool
Bybit Launches AED Fiat Referral Boost Campaign with 7,500 USDT Prize Pool

Terms and conditions apply. For more information about the limited-time promotion, restrictions and eligibility requirements, users may visit: Refer & Earn: AED Fiat Referral Boost — share a 7,500 USDT prize pool

For a step-by-step guide for AED deposits and withdrawals on Bybit, users may visit: Bybit Learn – How to deposit and withdraw AED on Bybit via Local bank transfer

Disclaimer:

This event is available only to users registered under the CMA license who joined Bybit on or after January 19, 2026. Participation is subject to eligibility requirements. This event is not available to residents of Dubai.

All newly registered users, excluding users from Brazil, India, and the United Kingdom, will be onboarded under Bybit Virtual Asset Platform Operator L.L.C S.P.C, an entity regulated by the Capital Market Authority (CMA) of the United Arab Emirates, for applicable product offerings.

#Bybit / #CryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

 

CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

By
Advertorial Desk
-

Key Highlights:

  • Excellent Safety Profile:  As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse Events (TRAEs). No excessive toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed, and the incidence of Grade ≥3 VEGF-related AEs was low.
  • Compelling Efficacy in Lung Cancer: CS2009 monotherapy demonstrates potentially transformative Phase I/II efficacy in Non-Small Cell Lung Cancer (NSCLC). In first-line NSCLC (PD-L1 tumor proportion score [TPS]≥50%), the overall response rate (ORR) reached 90%, with a disease control rate (DCR) of 100%. In AGA-negative, later-line NSCLC, ORR reached 25%.
  • Broad Antitumor Potential, Including in “Cold Tumors”: CS2009 monotherapy also demonstrates potent antitumor activity in later-line “cold” tumors that are not sensitive to PD-(L)1 mAb. An ORR of 40% was observed in patients with non-clear cell renal cell carcinoma (nccRCC), and an ORR of 33.3% in soft tissue sarcoma (STS), demonstrating its broad-spectrum therapeutic potential across multiple tumor types.
  • Accelerated Global Phase III Development Plan: The company plans to initiate the first wave of Phase III global multi-regional clinical trials (MRCT) for CS2009 by the end of 2026, targeting indications including NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC).
  • Data Presentation Plan: Updated Phase I and Phase II clinical data for CS2009 are expected to be disclosed at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and/or the European Society for Medical Oncology (ESMO) Congress.

SUZHOU, China, March 26, 2026 /PRNewswire/ — CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapeutics for oncology, immunology, inflammation, and other key disease areas, today announced encouraging clinical progress for CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, “Based on the latest clinical data for CS2009, we are confident in its potential to transform treatment paradigms across a broad spectrum of tumor types. Driven by its unique molecular design, CS2009 offers key mechanistic differentiation. To date, approximately 200 patients have been enrolled, demonstrating an outstanding safety profile with no observation of the severe toxicities commonly associated with combination regimens containing CTLA-4 and PD-(L)1 inhibitors.

In terms of efficacy, CS2009 has delivered compelling results across multiple indications: as a monotherapy in first-line NSCLC, it achieved an ORR of 90% in patients with PD-L1 TPS ≥ 50%. Significant benefits were also observed in historically difficult-to-treat ‘cold tumors’, including IO-pretreated advanced NSCLC, non-clear cell renal cell carcinoma (nccRCC), and soft tissue sarcoma (STS). Furthermore, Phase II studies evaluating CS2009 in combination with standard chemotherapy for first-line NSCLC, CRC, and other indications have yielded high objective response rates.

We look forward to presenting additional Phase I and Phase II data at this year’s ASCO and/or ESMO congresses. Currently, we are engaged in advanced partnership discussions with several global multinational pharmaceutical companies and aim to initiate multiple Phase III MRCT by the end of 2026.”

Rapid Patient Enrollment with Phase I/II Data Supporting Favorable Safety and Efficacy

The global multi-center Phase I/II clinical trial for CS2009 is actively ongoing in Australia and China, and its Investigational New Drug (IND) application for Phase II has been approved by the U.S. Food and Drug Administration (FDA). As of mid-March 2026, a total of 113 patients with advanced solid tumors have been enrolled in Phase I, with a median follow-up of approximately six months. 85 patients have been enrolled in Phase II.

1. Phase I Data Reinforces an Excellent Safety Profile:

  • CS2009 demonstrates a favorable safety and tolerability profile across all six dose levels evaluated, with no dose-limiting toxicities (DLTs) observed and the maximum tolerated dose (MTD) not reached.
  • The incidence of Grade ≥3 TRAEs was 23%; Grade ≥3 immune-related adverse events (irAEs) was 12.4%; and Grade ≥3 VEGF-related TRAEs was 4.4%. No excessive toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed.

2. Broad Antitumor Activity Observed in Heavily-Pretreated NSCLC and “Cold Tumors”:
Antitumor activity was observed across all dose levels, with robust efficacy signals in multiple tumor types.

  • At the 30 mg/kg, Q3W, CS2009 monotherapy achieved an ORR of 25% (6/24) and a DCR of 58.3% (14/24) in AGA-negative, later-line NSCLC patients.
  • Across dose levels, CS2009 monotherapy resulted in an ORR of 40% and a DCR of 100% in patients with nccRCC (n=5).
  • Across dose levels, CS2009 monotherapy resulted in an ORR of 33.3% and a DCR of 66.7% in patients with STS (n=9).

Phase II Data Reveal Transformative Potential of CS2009: 90% ORR with Monotherapy in First-Line NSCLC and Excellent Tolerability in Combination Regimens for First-Line NSCLC and CRC

The global multi-center Phase II clinical trial employs a multi-cohort parallel expansion design to evaluate the efficacy and safety of CS2009 monotherapy and combination therapy across 15 cohorts in 9 solid tumor types, including NSCLC, CRC, extensive-stage small cell lung cancer (ES-SCLC), cervical cancer (CC), gastric or gastroesophageal junction cancer (GC/GEJC), esophageal squamous cell carcinoma (ESCC), platinum-resistant ovarian cancer (PROC), triple-negative breast cancer (TNBC), and hepatocellular carcinoma (HCC).

1. Monotherapy Shows Striking Efficacy in First-line NSCLC:
CS2009 monotherapy (20 mg/30 mg, Q3W) achieved an ORR of 90% (9/10) and a DCR of 100% (10/10) in first-line NSCLC patients with PD-L1 TPS≥50% (n=10).

2. Combination Therapies Demonstrate Favorable Tolerability and Promising Efficacy
Safety data from multiple cohorts of CS2009 combined with standard chemotherapy showed that the combinations were well-tolerated across tumor types, with CS2009 without increasing the incidence or severity of chemotherapy-related adverse events. Initial potent antitumor activity was observed with combination treatment in first-line NSCLC and first-line CRC.

Efficient and Clearly-Defined Global Development Strategy

CStone plans to initiate the first set of Phase III global MRCTs for CS2009 by the end of 2026, focusing on indications including NSCLC, CRC, and SCLC.

Additional Phase I and Phase II clinical data for CS2009 are expected to be presented at the 2026 ASCO and/or ESMO Annual Meetings.

About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

CS2009, an innovative trispecific antibody designed and developed by CStone, with the potential to be first- or best-in-class. It combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional antitumor effects through synergistic actions. Specifically, anti-PD-1 activity reverses T cell exhaustion, anti-CTLA-4 activity promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells.

About CStone Pharmaceuticals

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com.

 

C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China

By
Advertorial Desk
-

CHENGDU, China and JANESVILLE, Wis., March 26, 2026 /PRNewswire/ — C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of a Master Radioisotope Supply Agreement with SHINE Technologies, LLC (Janesville, Wisconsin, USA), establishing a long-term, GMP-compliant supply of no-carrier-added lutetium-177 (n.c.a. Lu-177) and granting C-Ray exclusive distribution rights for this critical medical isotope across mainland China — excluding certain pre-existing SHINE partnerships.

Under the agreement, C-Ray will serve as SHINE’s exclusive distribution partner in mainland China, supplying n.c.a. Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies, and healthcare institutions. C-Ray will leverage its integrated, 28,000-square-meter Chengdu facility to provide downstream services including isotope conjugation, fill-and-finish, and quality control — delivering an end-to-end, ready-to-use isotope solution that substantially lowers the barrier for domestic companies to access internationally benchmarked radioisotope supply.

A Critical Isotope, a Strategic Supply

Lu-177 is among the most widely used therapeutic radioisotopes in targeted radiopharmaceutical therapy (TRT) globally, with approved and investigational applications across prostate cancer, neuroendocrine tumors (NETs), and a growing range of oncology indications. Its favorable physical half-life, beta emission energy, and co-imaging capability have made it the cornerstone isotope of the RDC field.

Supply security has long been a practical constraint on pipeline development in China. This partnership addresses that gap directly: SHINE’s Cassiopeia facility — one of North America’s largest n.c.a. Lu-177 production sites — will supply C-Ray under terms meeting both Chinese and U.S. regulatory standards, while C-Ray’s on-the-ground infrastructure ensures reliable last-mile delivery to clients across mainland China.

Leadership Perspectives

“This partnership is a significant step in C-Ray’s strategic supply diversification. Stable, multi-source isotope access is a core competitive advantage for us and our clients. Building on our leadership in Ac-225 supply, securing a reliable, high-quality source of n.c.a. Lu-177 — along with exclusive distribution rights — directly strengthens our clients’ pipeline continuity and reinforces our commitment to building a resilient radiopharmaceutical ecosystem in China. With our integrated platform and deep project management experience, we are confident in our ability to translate premium isotope supply into real patient outcomes and accelerated clinical translation across the industry.”
— Haitao Qiao, General Manager, C-Ray Therapeutics

“We are pleased to partner with C-Ray. This partnership reflects SHINE’s ability to serve growing demand for n.c.a. Lu-177 in China while maintaining strong supply for customers in the U.S. and other global markets. By combining C-Ray’s integrated development and manufacturing platform with our large-scale isotope production, we can help advance pipeline innovation and expand patient access to life-saving targeted radioligand therapies.”
— Greg Piefer, Founder and CEO, SHINE Technologies

About SHINE Technologies

Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy.

Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors. Learn more at www.shinefusion.com.

About C-Ray Therapeutics

C-Ray Therapeutics is a global CRDMO providing end-to-end radiopharmaceutical development services — from target validation and preclinical evaluation to IND-enabling studies, clinical supply, and commercial-scale cGMP manufacturing. Operating from its 28,000-square-meter Chengdu facility under China’s Class A Radiation Safety License, C-Ray supports 30+ radioisotopes and has delivered 70+ projects spanning diagnostic and therapeutic programs, including 5 programs at IND or IND-enabling stage, 5 in clinical supply, and 2 in Phase III clinical trials. For more information, visit www.c-raytherapeutics.com 

 

Another Month, Another Milestone: Bybit Earn’s Mantle Vault More than Doubles AUM in First Quarter of 2026

By
Advertorial Desk
-

DUBAI, UAE, March 26, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, announced another landmark achievement for Mantle Vault on Bybit On-Chain Earn on March 26, 2026. The game-changing yield-generating product launched in partnership with Mantle and Cian, has reached US$200 million in Assets Under Management (AUM), demonstrating explosive adoption and market demand for structured stablecoin yield solutions.

This milestone represents extraordinary momentum: the product has grown from its December 22, 2025 launch through a remarkable trajectory, hitting $100 million by early January, and now doubling to $200 million in just 94 days. The sustained growth reflects a fundamental market shift toward sophisticated, low-volatility investment structures during a period of measured macro consolidation.

Mantle Vault offers a unique access point to DeFi yield anchored in smart stablecoin strategies, and readily available on Bybit’s ultra user-friendly CeFi interface, helping users put the search for return on auto pilot.

How Mantle Vault Delivers Consistent Yield

Mantle Vault’s formula combines three key elements to deliver consistent performance:

  • Yield Generation: Users may earn returns through Ethena staking (sUSDe) and leveraged staking of USDT, USDC, and USDe on Aave V3 with potential additional incentives from Bybit and Mantle partnerships.
  • Market-Neutral Strategy: Mantle Vault’s proprietary market-neutral strategies helps minimize volatility exposure, allowing users to isolate yield from price risk, offering a critical advantage during periods of technical consolidation.
  • Smart Contract Security: All assets are secured by audited smart contracts on Aave V3 (Ethereum mainnet), providing institutional-grade custody standards on-chain.

Another Month, Another Milestone: Bybit Earn’s Mantle Vault More than Doubles AUM in First Quarter of 2026
Another Month, Another Milestone: Bybit Earn’s Mantle Vault More than Doubles AUM in First Quarter of 2026

In 2026, sophisticated DeFi products have transitioned from high-yield speculative markets to a more mature, institutional-grade infrastructure with strong fundamentals and market demand. 

The highly flexible product also offers zero subscription fees, and a low entry threshold starting at just 10 USDT or USDC, with most withdrawals processed within 0–3 days.

Terms and conditions apply. Past APR does not guarantee future APR. Returns may change due to Aave market demand, Ethena rewards or gas cost fluctuations. For details on qualification rules, restrictions, and eligibility, users may visit: [Bybit x Mantle x Cian] Introducing Mantle Vault: Stablecoin on-chain yield strategy built for stability, flexibility, and scale

#Bybit / #CryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

1...885886887...6,684Page 886 of 6,684